ZEVALIN DIN 02328674
Health Canada record
| Active ingredient(s) | IBRITUMOMAB TIUXETAN 3.2 MG |
|---|---|
| Dosage form | Kit; Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | V10XX02 IBRITUMOMAB TIUXETAN (90Y) |
| Original market date | 12-Sep-2018 |
| Current status date | 06-Dec-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Auro Pharma Inc — licence 101305, currently licensed, last inspection rating C (2023-09-27).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32284 | 2023-11-17 | New Drug Submission (NDS) | Administrative - Administrative Change in Product Ownership |